Bristol-myers Squibb Compnay

Institute of Organic Chemistry and Biochemistry of the Academy of

Rega Stichting, V.z.w.

Eli Lilly and Company

Kuo-Long Yu

Nicholas A Meanwell

Rita Civiello

Xiangdong Alan Wang

Keith D Combrink

Yi Zhang

Hatice Belgin Gulgeze

Ny Sin

Brian Lee Venables

Jan Willem Thuring

Joanne J Bronson

Zhiwei Yin

John E Starrett, Jr

John C Martin

Michael Enrico Richett

Muzammil M Mansuri

David R Tortolani

Bradley C Pearce

Deqi Guo

Jose Eduardo Lopez

Thomas John Bleisch

Mark R Krystal

Peter R Reczek

Scott Alan Jones

Christian Alexander Clarke

Kathleen F Kadow

Christopher W Cianci

Bradley C Pearc

Yaxiong Sun

Michael John Rodriguez

Esteban Dominguez

Miriam Filadelfa Del Prado

Jeffrey Alan Dodge

Charles Willis Iii Lugar

The present invention relates to compounds that inhibit activity of the histone lysine N-methyltransferase, Enhancer of Zeste Homolog 2 (EZH2), pharmaceutical compositions comprising the compounds, and methods of using the compounds to treat cancer, such as hematologic and solid tumors.

Inhibitors of EZH2

The present invention concerns antiviral compounds, their compositions, and use in the treatment of viral infections. More particularly, the invention provides benzimidazole derivatives for the treatment of respiratory syncytial virus infection.

Substituted benzimidazole antiviral agents

The present invention concerns antiviral compounds, their methods of preparation and their compositions, and use in the treatment of viral infections. More particularly, the invention provides heterocyclic substituted 2-methylbenzimidazole derivatives for the treatment of respiratory syncytial virus infection.

Substituted 2-methyl-benzimidazole respiratory syncytial virus antiviral agents

Heterocyclic substituted 2-methyl-benzimidazole antiviral agents

The present invention concerns antiviral compounds, their compositions, and use in the treatment of viral infections. More particularly, the invention provides benzimidazolone derivatives for the treatment of respiratory syncytial virus infection.

Benzimidazolone antiviral agents

The present invention concerns antiviral compounds, their methods of preparation and their compositions, and use in the treatment of viral infections. More particularly, the invention provides imidazopyridine and imidazopyrimidine derivatives (Formula I) for the treatment of respiratory syncytial virus infection.

Imidazopyridine and imidazopyrimidine antiviral agents

Compounds are provided that generally have the structure BCH.sub.2 CH(R)OCH.sub.2 P(O)(OH).sub.2, wherein B is a purinyl or pyrimidinyl base and R is C.sub.1-2 alkyl substituted with azido or amino, straight or branched alkenyl of 2-6 carbon atoms or alkynyl of 2-6 carbon atoms, together with the monester and diesters of such compounds with a C.sub.1-5 alkanol, and the corresponding salts, hydrates, solvates, the (R) or (S) isomers and the racemic (RS) mixtures thereof. The compounds have desirable antiviral activity.

Antiviral acyclic phosphonomethoxyalkylsubstituted alkenyl and alkynyl

The present invention relates to a compound of formula ##STR1## or a nontoxic pharmaceutically acceptable salt, physiologically hydrolyzable ester or solvate thereof, in which

Retinoid-like compounds

The present invention relates to a compound of formula I ##STR1## or a nontoxic pharmaceutically acceptable salt, physiologically hydrolyzable ester or solvate thereof, in which

The present invention provides chiral nucleotide analogs having the Formulas I and II ##STR1## and pharmaceutically acceptable salts and solvates thereof, and their pharmaceutical compositions for use in the treatment of viral infections, especially those caused by human immunodeficiency virus (HIV).

Use of chiral 2-(phosphonomethoxy)propyl guanines as antiviral agents

Growing community of inventors

Zionsville, IN, United States of America

Kuo-Long Yu